NCT02896231View on ClinicalTrials.gov

First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

October 31, 2019

Study Completion Date

October 31, 2019

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

PLB1001

PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.

Trial Locations (1)

510080

Guangdong General Hospital, Guangzhou

All Listed Sponsors
lead

Beijing Pearl Biotechnology Limited Liability Company

INDUSTRY

NCT02896231 - First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001 | Biotech Hunter | Biotech Hunter